• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Subsense Emerges from Stealth with $17M to Develop Non-Surgical Brain-Computer Interface

by Fred Pennic 02/18/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Subsense, Inc., a pioneering neurotechnology company announced its official launch and the closing of a $17 million seed funding round led by Golden Falcon Capital. 

– The company is developing a groundbreaking non-surgical, nanoparticle-based Brain-Computer Interface (BCI) with the potential to transform the treatment of neurological conditions.

Nanoparticle-Based Technology Aims to Enhance Treatment of Neurological Conditions

Subsense is co-founded by Tetiana Aleksandrova, a neurotechnology entrepreneur with a passion for developing innovative solutions for brain health and Artem Sokolov, a serial entrepreneur and early investor in successful companies like Asana, SoFi, and Coursera.Subsense’s innovative technology utilizes nanoparticles to establish a bidirectional connection between the brain and external devices. This approach allows for targeted neural stimulation and precise monitoring, opening up new possibilities for treating a wide range of neurological disorders.

“Brain-computer interfacing promises to unlock limitless human potential, but innovation has been held back by a lack of effective non-surgical approaches,” said Tetiana Aleksandrova, Subsense’s Chief Executive Officer. “By delivering nanoparticles that bind with receptors in the brain, Subsense can achieve more extensive connectivity with a far gentler approach.”

Collaborating with Leading Research Institutions

Subsense is collaborating with a consortium of leading neurological research institutions, including UC Santa Cruz and ETH Zurich, to accelerate the development and validation of its technology.

Targeting Neurological Conditions

Subsense’s initial focus is on developing therapies for neurological conditions such as:

  • Parkinson’s disease
  • Alzheimer’s disease
  • Epilepsy
  • Depression
  • Stroke
  • Chronic pain

Expanding the Possibilities of Brain-Computer Interfaces

Beyond therapeutic applications, Subsense is also exploring more expansive possibilities for its technology, including:

  • Sensorimotor recovery: Restoring vision, hearing, and movement.
  • Inner speech decoding: Translating thoughts into words.
  • AI integration: Merging the human brain with artificial neural networks.
  • External memory: Creating a backup and extension of human memory.
  • Mental health regulation: Monitoring and controlling emotions and mood.
  • Appetite control: Managing hunger and satiety signals.
  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |